

## Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use?  
1-inch 23G (66.4 kg)
2. Name the most common side effects a patient may experience when taking Invega Sustenna®.  
Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis, Neuroleptic Malignant Syndrome, QT Prolongation, Tardive Dyskinesia, metabolic changes, orthostatic hypotension
3. What black box warning is associated with this medication?  
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death
4. What are the standard *recommended* Day 1 and Day 8 initiation dosages for a person with schizophrenia?  
Day 1 = 234 mg  
Day 8 = 156 mg
5. What is the standard *recommended* maintenance dosage for a patient with schizophrenia?  
39-234 mg \*\*117 mg
6. What is the correct location for administration of the Day 1 and Day 8 initiation doses?  
Deltoid
7. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65mL/min?  
Day 1 = 156 mg  
Day 8 = 117 mg
8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment?  
78 mg

9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?

To establish tolerability

10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.

Clean injection site, Wear gloves, Hand hygiene

11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.

Ensure patients understand the risks & benefits of medication and make decisions about their treatment.